

Dengue Vaccine - QDENGGA (TAK-003)

Prelims: Current events of national and international importance | Health

Why in News?

Recently, the Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India's QDENGGA (TAK-003), making it the first dengue vaccine approved in India.

- **Type - Live-attenuated tetravalent vaccine**, protecting against all four dengue virus serotypes.
- **Dosage** - Two subcutaneous injections (0.5 ml each) are given three months apart.
- **Age Group** - Approved for individuals aged 4 to 60 years.
- **Screening** - Does not require pre-vaccination dengue screening, simplifying administration.
- **WHO Recommendation** - For dengue-endemic regions with high transmission.
- WHO prequalification enables procurement by UNICEF and PAHO.
- **Global Approvals** - Licensed in 43 countries across Asia, Latin America, and Europe.
- **Global Standing** - Aligns India with WHO-endorsed dengue control strategies.

Reference

[The Hindu | Dengue Vaccine](#)